Rituximab in the treatment of systemic sclerosis-associated interstitial lung disease: Comment on the article by Yoo

被引：3

作者：

Daoussis, Dimitrios ^{[1
]}

Andonopoulos, Andrew P. ^{[1
]}

机构：

[1] Univ Patras, Sch Med, Patras Univ Hosp, Div Rheumatol,Dept Internal Med, Patras 26504, Greece

来源：

RHEUMATOLOGY INTERNATIONAL | 2011年 / 31卷 / 06期

关键词：

Systemic sclerosis; Scleroderma; Rituximab; Interstitial lung disease; B cells; Fibrosis; Skin thickening; Rheumatic diseases;

D O I：

10.1007/s00296-010-1485-3

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Several lines of evidence from basic research indicate that B cells may contribute to the pathogenesis of systemic sclerosis. Clinical studies as well have provided preliminary data pointing to the direction that B-cell depletion with rituximab might be a therapeutic option for patients with this debilitating disease.

引用

页码：841 / 842

页数：2

共 50 条

[31] Molecular Insights Into Systemic Sclerosis-Associated Interstitial Lung Disease
Silver, Richard M.
Feghali-Bostwick, Carol A.
ARTHRITIS & RHEUMATOLOGY, 2014, 66 (03) : 485 - 487
[32] Successful experience of rituximab therapy for systemic sclerosis-associated interstitial lung disease with concomitant systemic lupus erythematosus
Sumida, Hayakazu
Asano, Yoshihide
Tamaki, Zenshiro
Aozasa, Naohiko
Taniguchi, Takashi
Takahashi, Takehiro
Toyama, Tetsuo
Ichimura, Yohei
Noda, Shinji
Akamata, Kaname
Miyazaki, Miki
Kuwano, Yoshihiro
Yanaba, Koichi
Sato, Shinichi
JOURNAL OF DERMATOLOGY, 2014, 41 (05): : 418 - 420
[33] B LYMPHOCYTE DEPLETION IN SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE AFTER TREATMENT WITH STANDARD AND LOW DOSES OF RITUXIMAB
Ananjeva, L.
Alexankin, A.
Desinova, O.
Starovojtova, M.
Volkov, A.
Alexandrova, E.
Nasonov, E.
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2014, 32 (02) : S84 - S85
[34] Successful treatment with rituximab in a Japanese patient with systemic sclerosis-associated interstitial lung disease resistant to oral steroid and cyclophosphamide
Numajiri, Hiroko
Yoshizaki, Ayumi
Ebata, Satoshi
Fukasawa, Takemichi
Yamashita, Takashi
Takahashi, Takehiro
Taniguchi, Takashi
Asano, Yoshihide
Sato, Shinichi
JOURNAL OF DERMATOLOGY, 2018, 45 (06): : E140 - E141
[35] RITUXIMAB FOR THE TREATMENT OF SYSTEMIC SCLEROSIS ASSOCIATED INTERSTITIAL LUNG DISEASE: A CASE SERIES
Ananyeva, L.
Desinova, O.
Starovoytova, M.
Koneva, O.
Yutkina, N.
Onsyannikova, O.
Volkov, A.
Aleksandrova, E.
ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 648 - 648
[36] RITUXIMAB EXPERIENCE IN PATIENTS WITH LONGSTANDING SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE: A SERIES OF 14 PATIENTS
Sari, A.
Guven, D.
Armagan, B.
Kilic, L.
Erden, A.
Akdogan, A.
ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 1262 - 1263
[37] Gastroesophageal reflux and serum biomarkers in systemic sclerosis-associated interstitial lung disease: comment on the article by Elhai et al Reply
Elhai, Muriel
Hoffmann-Vold, Anna Maria
Allanore, Yannick
ARTHRITIS & RHEUMATOLOGY, 2019, 71 (07) : 1204 - 1206
[38] Rituximab in Patients with Systemic Sclerosis-associated Interstitial Lung Disease A Systematic Review and Meta-Analysis
Macrea, Madalina
Ghazipura, Marya
Herman, Derrick
Barnes, Hayley
Knight, Shandra L.
Silver, Richard M.
Montesi, Sydney B.
Raghu, Ganesh
Hossain, Tanzib
ANNALS OF THE AMERICAN THORACIC SOCIETY, 2024, 21 (02) : 317 - 327
[39] Treatment of systemic sclerosis-associated interstitial lung disease: Lessons from clinical trials
Roofeh, David
Distler, Oliver
Allanore, Yannick
Denton, Christopher P.
Khanna, Dinesh
JOURNAL OF SCLERODERMA AND RELATED DISORDERS, 2020, 5 (2_SUPPL) : 61 - 71
[40] Efficacy of Mycophenolate Associated with Methotrexate as a Maintenance Treatment for Systemic Sclerosis-Associated Interstitial Lung Disease
Antonio Gonzalez-Nieto, Jose
Javier Martin-Suarez, Ignacio
Luis Gil-Munoz, Francisco
ARCHIVOS DE BRONCONEUMOLOGIA, 2011, 47 (11): : 575 - 575

← 1 2 3 4 5 →